

FOR IMMEDIATE RELEASE

February 3, 2021



Listed Company Name: Eisai Co., Ltd.
 Representative: Haruo Naito
 Representative Corporate Officer and CEO

Securities Code: 4523

Stock Exchange Listings: First Section of the Tokyo Stock Exchange

Inquiries: Sayoko Sasaki
 Vice President, Chief IR Officer
 Stakeholder Communications
 Phone +81-3-3817-5120

**Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for
 the Fiscal Year Ending March 31, 2021**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “the Company”) announced today that based on trends in business results, etc., the Company has revised its consolidated financial forecasts for the fiscal year ending March 31, 2021 (April 1, 2020 to March 31, 2021) previously announced on May 13, 2020, as follows.

1. Revised consolidated financial forecasts for the fiscal year ending March 31, 2021 (April 1, 2020 to March 31, 2021)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the period	Profit attributable to owners of the parent	Basic earnings per share
Previously announced forecast (A) (May 13, 2020)	719,000	88,000	90,000	67,500	67,000	233.00 yen
Currently revised forecast (B)	647,000	52,000	52,500	40,000	39,500	139.00 yen
Change in amount (B - A)	-72,000	-36,000	-37,500	-27,500	-27,500	
Percentage of change (%)	-10.0%	-40.9%	-41.7%	-40.7%	-41.0%	
(Reference) Business results for the fiscal year ended March 31, 2020	695,621	125,502	128,063	122,467	121,767	425.01 yen

2. Reason for revision of the consolidated financial forecasts

<Revenue>

Revenue has been revised focusing on major products as the impact of COVID-19 on business activities is lasting longer and has exceeded the earlier estimation. Also, a part of milestone payments from Merck & Co., Inc., Kenilworth, N.J., U.S.A., which was planned to be recorded in this fiscal year, is revised to be recorded in or after the next fiscal year due to the revision of sales for anticancer agent Lenvima. As a result, revenue is revised to ¥647.0 billion, down ¥72.0 billion from the previously announced forecasts.

<Profit>

The expenses related to clinical trials and promotional activities are estimated to decrease as a result of a delay in progress of some clinical trials and restraint of promotional activities due to COVID-19. On the other hand, in addition to decrease in gross profit due to recording of a part of milestone payments from Merck & Co., Inc., Kenilworth, N.J., U.S.A. in or after the next fiscal year, continuous aggressive resource investment will be made to projects that contribute to enhancing future corporate value, such as launch preparation assuming approval of anti-amyloid beta antibody aducanumab (jointly developed with Biogen Inc.) and research and development for indication expansion of Lenvima. As a result, operating profit is revised to ¥52.0 billion, down ¥36.0 billion from the previously announced forecasts. Profit attributable to owners of the parent for the year is estimated to be ¥39.5 billion, down ¥27.5 billion from the previously announced forecasts, as a result of decrease in operating profit. There are no changes to the total dividend for the fiscal year which is set at ¥160 per share (same amount as the previous fiscal year) with the fiscal year-end dividend is planned to be ¥80 per share.

*Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of February 3, 2021.
